MGMT Promoter Methylation Analysis

Last Modified: 3/3/2020 2:08:50 PM


Specimen Requirements:

FFPE tissue: Paraffin block
Collection Instructions: Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.
Transport & Storage: Temperature/Stability:  Refrigerate, and use cold pack for transport, cold pack should not be in direct contact with specimen.
Reference Range: Refer to Interpretive Results
Methodology: Molecular
Clinical Significance: Methylation (or hypermethylation) of the MGMT gene promoter down-regulates or inactivates the normal DNA-repair function of the MGMT enzyme, which can make tumors more susceptible to radiation or alkylating agent-based therapy. Testing is particularly useful in gliomas. About 45% of glioblastomas have MGMT methylation, and these patients show improved survival when treated with radiation and temzolomide over those patients with non-methylated tumors. Methylation has also been associated with improved survival in anaplastic gliomas, regardless of treatment. MGMT methylation has been reported in other tumors including colorectal, lung, and lymphoma, and alkylating agents and/or radiation therapy may be considered in these cases
Custom Panel: No

PRODUCTION SCHEDULE

Turn Around Time: 10 to 11 days
Sites Performed: NeoGenomics
PHL Test Code: PS
EPIC Test Code: N/A
Send Out Test Code: Soft Path - MGMT
Alternate Test Names: MGMT Gene Promoter; MGMT Methylation
CPT Coding: 81287

Go back to the top of the page.